Novo Nordisk Cuts Prices on Weight Loss & Diabetes Drugs | KVUE
In a significant move aimed at increasing access to crucial medications, Novo Nordisk announced plans to substantially reduce the list prices of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, as well as Rybelsus. The price cuts, reaching up to 50%, are slated to take effect on .
The decision comes as these medications have gained widespread attention – and faced affordability challenges – for their effectiveness in managing type 2 diabetes, and obesity. Wegovy, specifically, has become a prominent treatment option for weight loss, while Ozempic is primarily used for diabetes management. Rybelsus is an oral semaglutide medication also used to treat type 2 diabetes.
Currently, the list price for various doses of Ozempic and Wegovy will be lowered to $675, representing a 35% price reduction for Ozempic and a 50% reduction for Wegovy. This change also extends to Wegovy and Rybelsus pills.
Addressing Cost Barriers
According to Jamey Millar, executive VP of U.S. Operations for Novo Nordisk, the price reductions are a direct response to the need to make these medications more accessible. Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,
Millar stated. Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.
The company emphasized that the lower list price is particularly intended to benefit individuals with high-deductible health plans or co-insurance benefit designs, where out-of-pocket costs are directly tied to the list price of the medication.
New Access Options Through NovoCare Pharmacy
Beyond the list price reductions, Novo Nordisk is also introducing a new direct-to-patient pharmacy service, NovoCare Pharmacy, to further expand access. This online pharmacy will offer Wegovy at a cash price of $499 per month for all dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg – to uninsured patients or those with commercial insurance lacking coverage. Prior to access, a prescription from a healthcare provider is required.
NovoCare Pharmacy provides additional services, including benefit verification, refill reminders, and access to support from a NovoCare case manager. The medications will be fulfilled through CenterWell Pharmacy and shipped directly to patients’ homes.
Timing Coincides with Medicare Changes
The timing of these price cuts is also strategically aligned with upcoming changes to Medicare plans. The reductions will coincide with new, lower prices for Ozempic and Wegovy under Medicare plans for older Americans, potentially maximizing the benefit for a significant portion of the population.
Addressing Ongoing Supply Concerns
Novo Nordisk also confirmed that the recent shortages of Wegovy have been resolved. The company states that all dose strengths of the medication now meet or exceed current and projected U.S. Demand.
Implications for Patients and Healthcare
The announcement from Novo Nordisk represents a significant step towards addressing the financial barriers that have limited access to these increasingly important medications. While the list price reductions and the introduction of NovoCare Pharmacy are positive developments, the actual cost savings for patients will depend on their individual insurance coverage and healthcare plans.
The move also comes amidst growing competition in the GLP-1 receptor agonist market, with other pharmaceutical companies developing and marketing similar medications for weight loss and diabetes management. Eli Lilly, for example, has also recently cut prices for its weight-loss drug, Zepbound.
These developments are likely to continue shaping the landscape of obesity and diabetes care, potentially leading to increased treatment rates and improved health outcomes for millions of Americans. However, it’s important for patients to discuss the potential benefits and risks of these medications with their healthcare providers to determine the most appropriate treatment plan.